Fifth Third Bancorp lifted its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 34.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,553 shares of the company’s stock after buying an additional 2,194 shares during the period. Fifth Third Bancorp’s holdings in Praxis Precision Medicines were worth $2,491,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Ethic Inc. lifted its holdings in shares of Praxis Precision Medicines by 10.6% in the third quarter. Ethic Inc. now owns 2,181 shares of the company’s stock worth $635,000 after acquiring an additional 209 shares during the last quarter. Kornitzer Capital Management Inc. KS grew its holdings in shares of Praxis Precision Medicines by 44.3% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 11,575 shares of the company’s stock valued at $3,371,000 after purchasing an additional 3,555 shares during the last quarter. CenterBook Partners LP bought a new stake in shares of Praxis Precision Medicines during the 3rd quarter valued at approximately $11,223,000. Provenance Wealth Advisors LLC acquired a new position in Praxis Precision Medicines during the 3rd quarter worth approximately $128,000. Finally, Factory Mutual Insurance Co. acquired a new position in Praxis Precision Medicines during the 3rd quarter worth approximately $297,000. 67.84% of the stock is owned by hedge funds and other institutional investors.
Praxis Precision Medicines Stock Performance
Shares of PRAX stock opened at $300.43 on Friday. The company has a market capitalization of $8.40 billion, a price-to-earnings ratio of -23.47 and a beta of 2.85. Praxis Precision Medicines, Inc. has a 52-week low of $160.11 and a 52-week high of $392.70. The company has a 50-day simple moving average of $286.09 and a two-hundred day simple moving average of $314.25.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on PRAX shares. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $575.00 target price (up from $470.00) on shares of Praxis Precision Medicines in a report on Friday, August 21st. Needham & Company LLC restated a “buy” rating and set a $582.00 price target on shares of Praxis Precision Medicines in a report on Thursday, September 24th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $945.00 price objective on shares of Praxis Precision Medicines in a research note on Monday, August 17th. Guggenheim upped their price objective on Praxis Precision Medicines from $800.00 to $1,050.00 and gave the company a “buy” rating in a research note on Monday, November 16th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Praxis Precision Medicines from $700.00 to $725.00 and gave the company an “overweight” rating in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $660.50.
View Our Latest Stock Report on Praxis Precision Medicines
Praxis Precision Medicines Profile
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
Featured Articles
- Five stocks we like better than Praxis Precision Medicines
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding PRAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report).
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
